

Boston Scientific

Boston Scientific Acquires Office Complex in Marlborough, MA

(February 9, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed its purchase of the Addition Hill Corporate Center in Marlborough, Massachusetts. The site will initially serve as the new headquarters for the Company's Endosurgery group. Terms of the transaction were not disclosed.

The purchase includes three buildings totaling approximately 500,000 square feet. The site is located 15 miles west of Boston Scientific's corporate headquarters in Natick, Massachusetts.

"Our Endosurgery group has experienced strong growth, and we expect that growth to continue," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "This complex is very well suited to accommodate those growth needs. We look forward to working with the city of Marlborough and becoming a member of the community."

The Company anticipates relocating approximately 500 Endosurgery employees from its Natick and Watertown facilities into the new complex within the next year. Additional employees are expected to be located at the Marlborough facility in the future.

Boston Scientific's Endosurgery group is focused on technologies and products that improve quality of life, with a growing emphasis on women's health. The group's products are used by gastroenterologists, oncologists, pulmonologists, general surgeons, urologists, urogynecologists and gynecologists. The Marlborough complex will also house a Corporate Engineering group.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the commercialization of new technologies, operational efficiencies, and other factors described in the Company's filings with the Securities and Exchange Commission.

<https://stage.mediaroom.com/bostonscientific/news-releases?item=58712>